Visão geral da empresa
A biotechnology enterprise dedicated to the United States market, Curis, Inc. focuses on the discovery and development of novel drug candidates designed specifically for the treatment of human cancers. The company operates within the broader healthcare sector, with its specific industry classification falling under biotechnology, a field characterized by high research intensity and significant clinical trial requirements. As of the latest available data, the company maintains a market capitalization of $20.39M and employs a workforce of 20 individuals to support its operational and clinical objectives. The current market cap of $20.39M, combined with annual revenue of $9.44M, indicates that the company is a micro-cap entity with a relatively small market footprint compared to established pharmaceutical peers. These valuation metrics suggest the company is in an early or transitional stage of development, where market valuation is often driven more by potential clinical outcomes and intellectual property assets than by current cash flows or profitability. The small employee base of 20 reflects a lean organizational structure typical of biotechnology firms that are heavily reliant on external partnerships or grant funding to complement their internal research and development efforts.
Saúde financeira
Curis, Inc. reported a trailing twelve-month revenue of $9.44M, yet the company posted a net income of $-7,582,000 and an EBITDA of $-32,733,000 during the same period. The substantial gap between the positive revenue figure of $9.44M and the significant net loss of $-7,582,000 reveals a cost structure dominated by heavy expenditures in research, development, and clinical trial operations, which are standard but expensive for biotechnology firms in the clinical stage. The company's free cash flow stands at $-10,457,375, indicating that cash outflows for capital expenditures and working capital changes significantly exceeded operating cash generation, thereby limiting immediate financial flexibility without external financing. Analysis of the company's profitability margins shows a gross margin of -199.7%, an operating margin of -665.2%, and a profit margin of -80.3%; these deeply negative figures underscore the intense burn rate associated with developing oral small-molecule IRAK4 kinase inhibitors like Emavusertib before commercialization begins. On the balance sheet, the company holds $5.06M in cash against $1.62M in debt, resulting in a debt-to-equity ratio of 29.62, which suggests a capital structure that is currently leveraged but supported by a cash reserve sufficient to cover short-term obligations. However, the current ratio of 0.49 indicates that current assets are less than current liabilities, signaling potential short-term liquidity challenges that could require refinancing or additional capital raises in the near term. Additionally, the return on equity is listed as N/A due to the lack of profitable equity returns, while the return on assets is -67.2%, reflecting that the company's assets are currently generating negative returns on the capital invested by shareholders.
Avaliação de valorização
The valuation metrics for Curis, Inc. present a complex picture given the company's lack of consistent profitability, with a trailing P/E ratio (TTM) listed as N/A and a forward P/E of -0.53. The divergence between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing the stock based on future earnings expectations that are not yet realized, rather than historical performance. The price-to-book ratio is recorded at 1.21, suggesting that the market values the company at 21% above its book value, which can indicate a premium assigned to the company's intangible assets, such as its pipeline of clinical stage drug candidates. Alternative valuation metrics include a price-to-sales ratio of 2.16 and an EV/EBITDA of -0.52, which further highlight that traditional profitability-based multiples are not applicable, forcing reliance on sales-based or enterprise value-based comparisons to assess the stock's relative standing. In terms of trading range, the stock has a 52-week high of $3.13 and a 52-week low of $0.50, meaning the current price sits significantly below the 52-week high and above the 52-week low, reflecting high volatility in its recent price history. The beta value of 3.14 indicates that the stock is highly volatile, moving with more than three times the magnitude of the broader market, which introduces substantial risk for investors seeking stability in their portfolios.
Growth & Income
The company's financial trajectory is marked by a revenue growth rate of -66.0% year-over-year, while earnings growth is N/A due to the negative earnings base. The decline in revenue suggests a contraction in sales or a shift in the commercial landscape for the company's existing products, and since earnings are negative, the concept of earnings growing faster or slower than revenue is less relevant than the absolute loss incurred. Curis, Inc. does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all of its earnings, albeit negative ones, to reinvest into its drug development pipeline rather than distributing income to shareholders. This non-dividend profile is typical for biotechnology companies in the discovery and development phase, where capital is prioritized for advancing clinical candidates like Emavusertib through regulatory approval processes. Consequently, the overall growth and income profile is characterized by negative revenue growth and zero dividend income, reflecting a strategy focused entirely on capitalizing on future clinical successes rather than delivering immediate returns to investors.